● AI Equity Research · Healthcare

COMPASS Pathways plc (CMPS)

AI stock analysis · Medical Care Facilities · Last analyzed Aug 17, 2026

Compass Score

3.0/5

Call

Hold

Price

$13.45

AI Target

$23.75 +76.6%

AI Analyst Summary

COMPASS Pathways is a clinical-stage mental health company whose bull thesis rests entirely on its lead asset, COMP360 (psilocybin therapy for treatment-resistant depression), currently in Phase 3 trials — representing one of the most advanced psychedelic medicine programs globally. With 15 of 16 analysts rating the stock a Buy and a consensus price target implying ~77% upside, institutional conviction in the pipeline is exceptionally high. The primary risk is binary clinical outcome: a Phase 3 failure or regulatory setback would materially impair the stock given the company's pre-revenue, loss-making status.

Catalysts

Phase 3 COMP360 trial readout expected in 2025, representing the most significant de-risking event and a potential near-term re-rating catalyst
Potential FDA Breakthrough Therapy Designation progress or additional regulatory interactions that could accelerate the approval pathway for psilocybin therapy
Expanded pipeline data releases or partnering/licensing announcements that could validate the platform and provide non-dilutive capital

Risks

Binary Phase 3 trial risk: a failed primary endpoint for COMP360 in treatment-resistant depression could wipe out the majority of the stock's value given no commercial revenue base
Cash burn and dilution risk: as a loss-making clinical-stage company, continued R&D spend may require additional equity raises, potentially diluting existing shareholders
Regulatory and scheduling uncertainty: psilocybin remains a Schedule I controlled substance in the US; adverse policy shifts or a restrictive FDA stance could delay or block commercialization even with positive trial data

Fundamentals

Pe N/A (loss-making) · 1.0/5

Company is pre-profitability with a negative forward P/E of -9.4x. No trailing earnings available, which is typical for clinical-stage biopharma but represents a significant valuation risk.

Peg N/A · 3.0/5

PEG ratio is unavailable given the absence of positive earnings. Scored neutrally per guidelines for missing PEG in a clinical-stage context.

Analyst Rating Strong Buy consensus (1.3) · 5.0/5

15 Buy and 1 Hold from 16 analysts yields a consensus of 1.3 — a strong bullish signal well above the threshold for a score of 5. Broad analyst coverage with near-unanimous conviction.

Earnings Trend N/A (pre-revenue clinical stage) · 2.0/5

No meaningful earnings or revenue growth data available. The company remains in clinical development with no approved products generating commercial revenue. Losses are expected to persist near-term, warranting a below-average score.

Price Target Beat 2 of 4 quarters · 2.0/5

EPS beat rate of 2 out of the last 4 quarters is below average. For a pre-revenue company, EPS misses often reflect higher-than-expected R&D spend, suggesting execution variability on cost management.

Management Mixed execution signals · 3.0/5

Analyst confidence is high, but EPS beat consistency is weak at 50%. Management is navigating a complex clinical-stage pipeline, and capital allocation discipline is difficult to fully assess without commercial revenues. Scored neutrally.

● See the full picture

Get today's top-scored picks, ranked for you.

Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.

Start free for 3 days →

No credit card. Then $9/month. Cancel anytime.

How Compass scores stocks

Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →

Not financial advice. Compass is an analytical tool, not a registered investment adviser or broker-dealer. Scores and recommendations are generated by AI, may be inaccurate or out of date, and are not investment, financial, legal, or tax advice. Investing involves risk, including loss of principal. Do your own research and consult a licensed financial professional. About Compass.